Rigel Pharmaceuticals, Inc. discovers, develops, and provides novel therapies, focusing on hematologic disorders and cancer. The company offers FDA-approved products and collaborates with partners to market its products outside of the U.S. Rigel's clinical programs include an IRAK1/4 inhibitor, R289, which is evaluated in patients with lower-risk myelodysplastic syndrome.
